|
WO2020208612A1
|
|
Methods of anti-tumor therapy
|
|
WO2020183424A1
|
|
Methods of anti-tumor therapy
|
|
KR20200143385A
|
|
Bispecific antibody against MOSPD2 and T cell or NK cell specific molecule
|
|
EP3697451A1
|
|
Diagnostic methods for anti-angiogenic agent therapy
|
|
CN108135933A
|
|
Protein 2 and cancer containing motile sperm structural domain
|
|
AU2016303472A1
|
|
Motile sperm domain containing protein 2 and inflammation
|
|
CA2968790A1
|
|
Oxidized lipids and treatment or prevention of fibrosis
|
|
US2016304544A1
|
|
Oxidized lipids
|
|
US2016121001A1
|
|
Methods of inducing responsiveness to anti-angiogenic agent
|
|
CN105025931A
|
|
Treatment methods using adenovirus
|
|
US2013237720A1
|
|
High-purity phospholipids
|
|
EP2814497A2
|
|
Methods for treating psoriasis and vascular inflammation
|
|
CA2858789A1
|
|
Treatment of inflammation
|
|
US2013079540A1
|
|
High-purity phospholipids
|
|
SG11201400208PA
|
|
Formulations and dosage forms of oxidized phospholipids
|
|
SG10201509400TA
|
|
Formulations and dosage forms of oxidized phospholipids
|
|
AU2012204128A1
|
|
Polypeptides and Polynucleotides Encoding Same and Use Thereof in the Treatment of Medical Conditions Associated with Ischemia
|
|
WO2012052878A1
|
|
Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
|
|
AU2011205076A1
|
|
Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
|
|
IL212721D0
|
|
Oxidized lipid compounds and uses thereof
|
